MA28268A1 - Composes et techniques de traitement de la dyslipidemie - Google Patents
Composes et techniques de traitement de la dyslipidemieInfo
- Publication number
- MA28268A1 MA28268A1 MA28999A MA28999A MA28268A1 MA 28268 A1 MA28268 A1 MA 28268A1 MA 28999 A MA28999 A MA 28999A MA 28999 A MA28999 A MA 28999A MA 28268 A1 MA28268 A1 MA 28268A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- methods
- treating dyslipidemia
- treating
- dyslipidemia
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 title 1
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50973603P | 2003-10-08 | 2003-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28268A1 true MA28268A1 (fr) | 2006-11-01 |
Family
ID=34465112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28999A MA28268A1 (fr) | 2003-10-08 | 2006-05-03 | Composes et techniques de traitement de la dyslipidemie |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7749992B2 (enExample) |
| EP (2) | EP2098512A1 (enExample) |
| JP (1) | JP4773969B2 (enExample) |
| KR (1) | KR20060085675A (enExample) |
| CN (1) | CN1863778A (enExample) |
| AT (1) | ATE442358T1 (enExample) |
| AU (1) | AU2004282101A1 (enExample) |
| BR (1) | BRPI0414186A (enExample) |
| CA (1) | CA2537942A1 (enExample) |
| CY (1) | CY1110537T1 (enExample) |
| DE (1) | DE602004023100D1 (enExample) |
| DK (1) | DK1670768T3 (enExample) |
| EA (1) | EA200600737A1 (enExample) |
| EC (1) | ECSP066484A (enExample) |
| ES (1) | ES2332051T3 (enExample) |
| HR (1) | HRP20090581T1 (enExample) |
| IL (1) | IL173819A0 (enExample) |
| MA (1) | MA28268A1 (enExample) |
| MX (1) | MXPA06003927A (enExample) |
| NO (1) | NO20062074L (enExample) |
| PL (1) | PL1670768T3 (enExample) |
| PT (1) | PT1670768E (enExample) |
| SI (1) | SI1670768T1 (enExample) |
| WO (1) | WO2005037796A1 (enExample) |
| ZA (1) | ZA200602888B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE433984T1 (de) * | 2004-03-26 | 2009-07-15 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidämie |
| CA2570688A1 (en) | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| CN103833636B (zh) * | 2014-03-31 | 2015-09-02 | 武汉武药制药有限公司 | 一种莫扎伐普坦中间体的合成方法 |
| EP3328835B1 (en) * | 2015-07-31 | 2022-10-12 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2018155260A1 (ja) * | 2017-02-23 | 2018-08-30 | 株式会社Ihi | Ｏｈラジカル検出プローブ、ｏｈラジカル測定装置、および、ｏｈラジカル測定方法 |
| CN113195475A (zh) | 2018-10-24 | 2021-07-30 | Viiv保健英国第五有限公司 | 人免疫缺陷病毒复制的抑制剂 |
| BR112022020933A2 (pt) | 2020-04-15 | 2022-12-06 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| CN113636977B (zh) * | 2021-09-01 | 2022-12-20 | 温州大学 | 2-芳基苯并氮杂卓及其衍生物的合成方法 |
| CN117088814A (zh) * | 2023-02-16 | 2023-11-21 | 烟台大学 | 一种三氟甲硫化氮杂-8/9元环化合物的制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2905909B2 (ja) * | 1991-04-19 | 1999-06-14 | 大塚製薬株式会社 | バソプレシン拮抗剤 |
| TW270927B (enExample) | 1992-10-16 | 1996-02-21 | Otsuka Pharma Co Ltd | |
| US5484783A (en) | 1994-03-24 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives |
| HUT75160A (en) | 1994-03-24 | 1997-04-28 | Merrell Pharma Inc | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives |
| DK0765314T3 (da) | 1994-06-15 | 2003-08-25 | Otsuka Pharma Co Ltd | Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer |
| GB9523526D0 (en) | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| JPH09214746A (ja) | 1996-02-02 | 1997-08-15 | Ricoh Co Ltd | 画像出力システム及び画像形成装置 |
| US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US6333349B1 (en) | 1997-02-26 | 2001-12-25 | Aventis Pharma Deutschland Gmbh | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法 |
| JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
| US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| HN2000000203A (es) | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| US6664522B2 (en) * | 2000-03-30 | 2003-12-16 | Homer L. Spencer | Method and apparatus for sealing multiple casings for oil and gas wells |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| DK1383734T3 (da) | 2001-04-30 | 2006-05-15 | Pfizer Prod Inc | Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater |
| HUP0400263A2 (hu) | 2001-06-21 | 2005-03-29 | Pfizer Products Inc. | Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény |
| DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| JP2005522424A (ja) | 2002-02-01 | 2005-07-28 | ファイザー・プロダクツ・インク | コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態 |
| ATE493456T1 (de) | 2002-07-01 | 2011-01-15 | Cytec Surface Specialties Sa | Wasserverdünnbare polymervorläufer sowie herstellung und verwendung davon |
| ES2277142T3 (es) | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | Compuesto de dibencilamina y su uso medicinal. |
| MXPA05003456A (es) | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
| EP1601655A2 (en) | 2003-03-04 | 2005-12-07 | Takasago International Corporation | Method for producing optically active amines |
| US20040204450A1 (en) | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| WO2005033082A2 (en) | 2003-09-30 | 2005-04-14 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
| ATE433984T1 (de) | 2004-03-26 | 2009-07-15 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidämie |
| CA2570688A1 (en) | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
-
2004
- 2004-10-07 BR BRPI0414186-5A patent/BRPI0414186A/pt not_active Application Discontinuation
- 2004-10-07 KR KR1020067006837A patent/KR20060085675A/ko not_active Ceased
- 2004-10-07 PT PT04793889T patent/PT1670768E/pt unknown
- 2004-10-07 ES ES04793889T patent/ES2332051T3/es not_active Expired - Lifetime
- 2004-10-07 CN CNA2004800295407A patent/CN1863778A/zh active Pending
- 2004-10-07 US US10/574,649 patent/US7749992B2/en not_active Expired - Fee Related
- 2004-10-07 EP EP09157118A patent/EP2098512A1/en not_active Withdrawn
- 2004-10-07 DK DK04793889T patent/DK1670768T3/da active
- 2004-10-07 HR HR20090581T patent/HRP20090581T1/hr unknown
- 2004-10-07 SI SI200431294T patent/SI1670768T1/sl unknown
- 2004-10-07 PL PL04793889T patent/PL1670768T3/pl unknown
- 2004-10-07 MX MXPA06003927A patent/MXPA06003927A/es not_active Application Discontinuation
- 2004-10-07 AT AT04793889T patent/ATE442358T1/de active
- 2004-10-07 CA CA002537942A patent/CA2537942A1/en not_active Abandoned
- 2004-10-07 EA EA200600737A patent/EA200600737A1/ru unknown
- 2004-10-07 JP JP2006533949A patent/JP4773969B2/ja not_active Expired - Fee Related
- 2004-10-07 EP EP04793889A patent/EP1670768B1/en not_active Expired - Lifetime
- 2004-10-07 DE DE602004023100T patent/DE602004023100D1/de not_active Expired - Lifetime
- 2004-10-07 WO PCT/US2004/030907 patent/WO2005037796A1/en not_active Ceased
- 2004-10-07 AU AU2004282101A patent/AU2004282101A1/en not_active Abandoned
-
2006
- 2006-02-20 IL IL173819A patent/IL173819A0/en unknown
- 2006-04-05 EC EC2006006484A patent/ECSP066484A/es unknown
- 2006-04-07 ZA ZA200602888A patent/ZA200602888B/en unknown
- 2006-05-03 MA MA28999A patent/MA28268A1/fr unknown
- 2006-05-08 NO NO20062074A patent/NO20062074L/no not_active Application Discontinuation
-
2009
- 2009-11-05 CY CY20091101151T patent/CY1110537T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1670768E (pt) | 2009-11-20 |
| IL173819A0 (en) | 2006-07-05 |
| KR20060085675A (ko) | 2006-07-27 |
| CY1110537T1 (el) | 2015-04-29 |
| EP1670768B1 (en) | 2009-09-09 |
| WO2005037796A1 (en) | 2005-04-28 |
| DK1670768T3 (da) | 2009-11-09 |
| EP1670768A1 (en) | 2006-06-21 |
| DE602004023100D1 (de) | 2009-10-22 |
| ECSP066484A (es) | 2006-10-10 |
| JP4773969B2 (ja) | 2011-09-14 |
| CN1863778A (zh) | 2006-11-15 |
| NO20062074L (no) | 2006-05-08 |
| MXPA06003927A (es) | 2008-02-07 |
| JP2007508301A (ja) | 2007-04-05 |
| EA200600737A1 (ru) | 2006-10-27 |
| ATE442358T1 (de) | 2009-09-15 |
| ES2332051T3 (es) | 2010-01-25 |
| AU2004282101A1 (en) | 2005-04-28 |
| BRPI0414186A (pt) | 2006-10-31 |
| HRP20090581T1 (hr) | 2009-12-31 |
| EP2098512A1 (en) | 2009-09-09 |
| SI1670768T1 (sl) | 2010-01-29 |
| ZA200602888B (en) | 2007-11-28 |
| US20070254869A1 (en) | 2007-11-01 |
| CA2537942A1 (en) | 2005-04-28 |
| PL1670768T3 (pl) | 2010-01-29 |
| US7749992B2 (en) | 2010-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110398T1 (el) | Ενωσεις για την αγωγη της δυσλιπιδαιμιας | |
| CY1110537T1 (el) | Ενωσεις και μεθοδοι για την αγωγη της δυσλιπιδαιμιας | |
| SE0301373D0 (sv) | Novel compounds | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| SE0302811D0 (sv) | Novel compounds | |
| EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| SE0301446D0 (sv) | New Compounds | |
| ATE423122T1 (de) | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) | |
| PL376324A1 (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
| SE0302139D0 (sv) | Novel compounds | |
| SE0303541D0 (sv) | New compounds | |
| MY141583A (en) | Novel fused heterocycles and uses thereof | |
| DE602004031410D1 (de) | Inden derivate als pharmazeutika | |
| NO20054361D0 (no) | Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte | |
| SE0303280D0 (sv) | Novel compounds | |
| ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
| SE0302755D0 (sv) | Novel compounds | |
| UY29012A1 (es) | "oxazolididonas y composiciones y metodos relacionados" | |
| FR2894579B1 (fr) | Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique. | |
| SE0301697D0 (sv) | Novel fused heterocycles and uses thereof |